Clinical trials: Acute Ischemic Stroke AIS
Stroke
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
The present study is to be conducted based on the AIS patient data collected from CNSR I, II, and III. The primary objectives are: To investigate the temporal changes in the proportion of intravenous recombinant plasminogen…
- Trial name
- NCT04290494
- Testing
- IV rtPA (intravenous recombinant plasminogen activator)
- Where
- China
- Volunteers
- 42,188 people
- Sponsor
- Boehringer Ingelheim
AIS, Acute Ischemic Stroke
A Prospective, Multi-center and Randomized Controlled Trial of Tianyi Revascularization Device in Acute Ischemic Stroke
This is a prospective, randomized, single blind, concurrent controlled, multi-center study. Patients presenting with symptoms of acute ischemic stroke who have evidence of a large vessel occlusion in the cerebral circulation.
- Conditions
- AIS, Acute Ischemic Stroke, Large Vessel Occlusion, Thrombectomy
- Trial name
- NCT05496361
- Testing
- Tianyi Revascularization Device, Solitaire FR Revascularization Device
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Suzhou Zenith Vascular SciTech Limited
Stroke, Acute
An Open, Study to Assess the Safety of RGTA® (OTR4132) in Patients With Acute Ischemic Stroke (AIS)
RGTA® (ReGeneraTing Agent) are synthetic polysaccharides mimicking extra-cellular matrix scaffold elements and protective agents called Heparan Sulphates (HSPGs). OTR4132-MD is provided as a sterile injectable medical device.
- Trial name
- MATRISS (NCT04083001)
- Testing
- OTR4132MD
- Where
- 3 sites in France
- Volunteers
- 19 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
Acute Ischemic Stroke
Safety and Efficacy of J147 in Acute Ischemic Stroke
The goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients.
- Trial name
- JUMPSTART (NCT07430917)
- Testing
- J147 Emulsion for Injection
- Where
- 5 sites in United States
- Volunteers
- 196 people
- Sponsor
- Abrexa Pharmaceuticals, Inc.
Acute Stroke, Ischemic Stroke
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and…
- Conditions
- Acute Stroke, Ischemic Stroke, Stroke
- Trial name
- ReMEDy2 (NCT05065216)
- Testing
- Recombinant human tissue kallikrein
- Where
- 86 sites in United States, Belgium and 8 more
- Volunteers
- 728 people
- Sponsor
- DiaMedica Therapeutics Inc
Acute Ischemic Stroke
ANAIS Study to Confirm the Safety and Performance of the ANA 5F Advanced Neurovascular Access®
Prospective, single-arm, multi-center study to assess the safety and performance of the ANA 5F Advanced Neurovascular Access®, in combination with a stent retriever in patients with acute ischemic stroke.
- Trial name
- ANAIS (NCT05409430)
- Testing
- Neurothrombectomy
- Where
- 3 sites in Spain
- Volunteers
- 43 people
- Sponsor
- Anaconda Biomed S.L.
AIS
NBP in Adult Patients With Acute Ischemic Stroke (AIS)
This is a Phase 2 multicenter, randomized, double-blind, placebo-controlled, add-on to standard of care study of NBP softgel capsules for the treatment of mild to moderate AIS in adults.
- Trial name
- NCT02905565
- Testing
- NBP Softgel Capsules
- Where
- 21 sites in United States
- Volunteers
- 177 people
- Sponsor
- CSPC-NBP Pharmaceutical Co., Ltd.
Stroke, Acute Ischemic Stroke
Mobilisation After Endovascular Stroke Treatment
The goal of this observational study is to learn how the timing of mobilisation after endovascular thrombectomy (EVT) affects complications in patients with acute ischaemic stroke.
- Conditions
- Stroke, Acute Ischemic Stroke, Acute Ischemic Stroke AIS, Endovascular Thrombectomy
- Trial name
- MAESTRO (NCT07860333)
- Testing
- Mobilisation
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 400 people
- Sponsor
- Karolinska Institutet
Acute Ischemic Stroke (AIS)
Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke
- Trial name
- ARPEGGIO (NCT05585606)
- Testing
- scp776 (1.9 mg/kg), scp776 (3.8 mg/kg), scp776 (4.8 mg/kg)
- Where
- 22 sites in United States
- Volunteers
- 120 people
- Sponsor
- Silver Creek Pharmaceuticals
Acute Ischemic Stroke Patients, Acute Ischemic Stroke
Guiding Catheters in Endovascular Stroke Therapy - Are Balloon Guided Catheters Superior?
The BEST study is an academically initiated, single-center, prospective, randomized controlled clinical trial investigating the potential advantages and disadvantages of using a guide catheter with or without a balloon in the…
- Conditions
- Acute Ischemic Stroke Patients, Acute Ischemic Stroke, Acute Ischemic Stroke AIS
- Trial name
- BEST (NCT07478042)
- Testing
- Ballon guide catheter, Guide catheter without balloon
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- University Hospital Heidelberg
Acute Ischemic Stroke (AIS)
Deep Learning Enabled Endovascular Stroke Therapy Screening in Community Hospitals
After onset of Acute Ischemic Stroke (AIS), every minute of delay to treatment reduces the likelihood of a good clinical outcome.
- Trial name
- NCT05838456
- Testing
- Viz.AI software
- Where
- United States
- Volunteers
- 443 people
- Sponsor
- The University of Texas Health Science Center, Houston
Stroke
Prognostic Value of Transcranial Doppler Ultrasound in the Clinical Evolution of Patients With Acute Ischemic Stroke. The TRADE-AIS Study
This prospective observational study aims to determine whether specific parameters measured by transcranial Doppler ultrasound (TCD) can predict clinical outcomes in patients with acute ischemic stroke (AIS).
- Trial name
- TRADE-AIS (NCT07004790)
- Testing
- Transcranial Doppler Ultrasound
- Volunteers
- 50 people
- Sponsor
- Jose Ivan Rodriguez de Molina Serrano
Acute Ischemic Stroke, Atrial Fibrillation
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
The goal of this clinical trial is to compare the safety and effectiveness of anticoagulation combined with antiplatelet therapy in acute ischemic stroke (AIS) patients with concomitant non-valvular atrial fibrillation (NVAF) and…
- Conditions
- Acute Ischemic Stroke, Atrial Fibrillation, Stenosis, Carotid, Intracranial Atherosclerosis
- Trial name
- ALLY (NCT06058130)
- Testing
- Anticoagulant Oral, Anticoagulation combined with antiplatelet therapy
- Where
- 2 sites in China
- Volunteers
- 2,171 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Acute Ischemic Stroke
Metformin in Acute Ischemic Stroke
The goal of this clinical trial is to study the efficacy of oral Metformin in Acute Ischemic Stroke (AIS). The main hypothesis is to study the efficacy of oral Metformin in patients with acute ischemic stroke presenting within 72…
- Trial name
- NCT07899307
- Testing
- Metfomin
- Where
- 4 sites in India
- Volunteers
- 440 people
- Sponsor
- All India Institute of Medical Sciences
Acute Ischemic Stroke AIS, Stroke Acute
ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design.
- Conditions
- Acute Ischemic Stroke AIS, Stroke Acute, Stroke, Acute, Stroke Ischemic
- Trial name
- ACT-WHEN (NCT06320431)
- Testing
- Tenecteplase
- Where
- 24 sites in Australia, Canada
- Volunteers
- 4,000 people
- Sponsor
- University of Calgary
Acute Ischemic Stroke
Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment
Butylphthalide, as a well-known neuroprotective medication, is a family of compounds initially isolated from the seeds of Apium graveolens Linn, of which active ingredient is dl-3-N-butylphthalide (dl-NBP).
- Trial name
- BAST (NCT03539445)
- Testing
- Butylphthalide
- Where
- China
- Volunteers
- 1,216 people
- Sponsor
- Beijing Tiantan Hospital
Ischemic Stroke
Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS
The aim of the study is to determine if single-bolus recombinant nonimmunogenic staphylokinase is effective and save thrombolytic agent in patients with ischemic stroke in comparison to alteplase.
- Trial name
- NCT03151993
- Testing
- Recombinant staphylokinase, Alteplase
- Where
- 18 sites in Russia
- Volunteers
- 336 people
- Sponsor
- Supergene, LLC
Acute Ischemic Stroke, Large Vessel Occlusion
Evaluation of the CONDA Stent Retriever in Acute Ischemic Stroke
The goal of this study is to evaluate the safety and performance of the CONDA stent retriever in patients with acute ischemic stroke due to large vessel occlusion, treated within 24 hours of symptom onset.
- Trial name
- ARTEMIS (NCT07174505)
- Testing
- Mechanical Thrombectomy using the CONDA Stent Retriever
- Where
- 2 sites in Hungary, Spain
- Volunteers
- 50 people
- Sponsor
- Anaconda Biomed S.L.
Acute Stroke, Mechanical Thrombectomy
BraiN20® Monitoring in Acute Stroke Undergoing Thrombectomy
N20 somatosensory evoked potential (SEP) response shows high predictive accuracy of functional recovery in patients with acute ischemic stroke (AIS) undergoing endovascular thrombectomy (EVT).
- Trial name
- PROMISE20 (NCT06149754)
- Testing
- BraiN20(R) monitoring of N20 somatosensory evoked potential
- Where
- 3 sites in Spain
- Volunteers
- 65 people
- Sponsor
- Fundació Institut Germans Trias i Pujol
Acute Ischemic Stroke
Angong Niuhuang Pills With Different Bovine Bezoar Formulation Sources in the Treatment of AIS
This study is a single-center, open-label, controlled clinical trial that prospectively enrolls 100 participants (40 in the Z11020076 group, 40 in the Z20063878 group, and 20 in the blank control group) to collect clinical data…
- Trial name
- NCT06883110
- Testing
- Z11020076, Z20063878
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tongji Hospital